Director John Jenkins adopts 10b5-1 plan to sell up to 5,436 CRBP shares

Corbus Pharmaceuticals Holdings, Inc.

Plan covers up to 5,436 shares of common stock, effective November 30, 2024.
Plan terminates on November 29, 2025, per Rule 10b5-1(c) affirmative defense.
Dr. Jenkins is a member of the board of directors of Corbus Pharmaceuticals.
Trading plan adopted on August 29, 2024; sales may begin after the 90-day cooling-off period.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.